scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

scPharmaceuticals reports Q4 loss, sees growth potential with FUROSCIX

scPharmaceuticals' financials show investment in the FUROSCIX launch, with a net loss reported for Q4 2022 and the full year.
FUROSCIX's commercial success, distribution partnerships, and evolving physician perceptions are key strengths for the company.
Challenges lie in reimbursement processes, achieving target co-pays, and aligning on optimal FUROSCIX use timing among doctors.
Opportunities include the substantial market potential, targeted outreach to hospitals, and driving prescriptions through in-services.

scPharmaceuticals reports mixed Q1 results, FUROSCIX shows promising market reception

scPharmaceuticals reported mixed financials with strong revenue but a net loss in Q1 2023.
FUROSCIX's success in the market and positive feedback position it well for future growth.
Challenges exist in managing expenses and securing broader coverage for the treatment.
Opportunities lie in expanding patient access, improving authorization rates, and driving revenue growth.

scPharmaceuticals reports $1.6M Q2 revenue, eyes FDA filing expansion

scPharmaceuticals (SCPH) reported mixed financial results for Q2, with strong revenue but a net loss. The company is focused on expanding FUROSCIX's market reach, improving gross to net discount, and enhancing brand awareness through marketing efforts. Anticipated FDA filing and plans for indication expansion signal growth potential.

scPharmaceuticals reports stellar Q3 performance, eyes market expansion opportunities

scPharmaceuticals delivered robust financial results in Q3 2023, driven by strong revenue growth and improved gross profit margins.
Strategic initiatives to expand market reach and access to FUROSCIX position the company for sustained growth and market penetration.
While facing challenges in pricing dynamics and regulatory expansions, scPharmaceuticals holds significant opportunities for growth and value creation.

scPharmaceuticals reports strong Q4 earnings and eyes market expansion

scPharmaceuticals showcased robust financial performance and strategic growth initiatives in Q4 2023, driven by FUROSCIX sales.
While facing market complexities and operational challenges, the company maintains a strong cash position and optimistic outlook for future initiatives.
Opportunities lie in market access negotiations, streamlined regulatory processes, and expanding product coverage, positioning scPharmaceuticals for continued success.

scPharmaceuticals reports Q1 challenges but remains optimistic for 2024

scPharmaceuticals faced challenges in Q1 due to a cyber attack and increased expenses, but showed resilience with positive trends in FUROSCIX utilization and growth initiatives. The company remains optimistic for continued momentum and life cycle initiatives in 2024.

scPharmaceuticals reports robust Q2 performance and regulatory wins

scPharmaceuticals delivered strong financial performance and regulatory milestones in Q2 2024, positioning the company for growth.
While facing operational challenges and competitive pressures, the company's strategic strengths and opportunities offer avenues for future success.
With a focus on innovation, market expansion, and financial stability, scPharmaceuticals is poised for continued growth and value creation.
Investors can be optimistic about scPharmaceuticals' progress and potential in the pharmaceutical market based on the Q2 performance and strategic initiatives.

scPharmaceuticals reports revenue growth and strategic advancements in Q3

scPharmaceuticals demonstrated revenue growth and strategic advancements in Q3 2024, underpinned by strong FUROSCIX sales and key initiatives.
While facing challenges such as ongoing losses and pricing dynamics, the company's focus on innovation and commercial progress positions it well for future growth.
With opportunities in seasonal demand, market expansion, and a solid financial base, scPharmaceuticals is poised for continued development and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Anupam Leesy - Leerink Partners Stacy Ku - TD Cowen Douglas Tsao - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to scPharmaceuticals' Third Quarter 2024 Earnings Conference Call.

scPharmaceuticals Inc. (SCPH) Q3 2024 Earnings Call Transcript

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago.

ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates

Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13 th , at 4:30pm ET BURLINGTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode.

scPharmaceuticals Inc. (SCPH) Q2 2024 Earnings Call Transcript

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago.

ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates

Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth initiatives including label expansion for heart failure, sNDA submission for CKD, and positive topline pivotal PK data for our Autoinjector Company to host investor conference call and webcast today, Wednesday, August 14 th , at 4:30pm ET BURLINGTON, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the second quarter ended June 30, 2024, and provided a business update.

scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a public offering price of $4.00 per share and, to select investors, in lieu of common stock, pre-funded warrants to purchase up to 500,000 shares of common stock at a purchase price of $3.999 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrants. The pre-funded warrants have an exercise price of $0.001 per share.  All of the shares and the pre-funded warrants are being offered by scPharmaceuticals. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of common stock from the Company at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on August 13, 2024, subject to the satisfaction of customary closing conditions.

scPharmaceuticals Announces Pricing of $50.0 Million Public Offering

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million

scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association (NYHA) functional class

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental New Drug Application (sNDA) submission to the FDA by year-end 2024 BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced positive topline results from the pharmacokinetic (PK) study of SCP-111, an investigational, low volume, pH neutral formulation of furosemide administered via an autoinjector as an alternative to the current on-body infusor used with FUROSCIX.

scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector

BURLINGTON, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced a proposed underwritten public offering of shares (“Shares”) of its common stock or, in lieu of Shares, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Shares (the “Offering”). scPharmaceuticals also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of Shares offered in the Offering. All Shares and Pre-Funded Warrants to be sold in the Offering will be offered by scPharmaceuticals. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.

scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

AirSculpt Technologies

Kadant

Mondee Holdings Inc

Trupanion

Verrica Pharmaceuticals Inc

Westrock Coffee Holdings LLC

Short-squeeze stocks represent one of the boldest forms of contrarianism available. Simply put, it's a showdown between the bears that are attempting to profit from the downturn of a public enterprise.

7 Short-Squeeze Stocks That Could Beat Down the Bears

BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 5:00PM ET. Mr. Tucker will also be meeting with investors that day.

scPharmaceuticals to Present at the Jefferies Global Healthcare Conference

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP of Commercial Rachael Nokes - CFO Conference Call Participants Glen Santangelo - Jefferies Stacy Ku - TD Cowen Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Naz Rahman - Maxim Group Douglas Tsao - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the scPharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

scPharmaceuticals Inc. (SCPH) Q1 2024 Earnings Call Transcript

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.30 per share a year ago.

ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates

Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New York on Monday, May 20, at 11:00AM ET. Mr. Tucker will also be meeting with investors during the event.

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.

News for scPharmaceuticals Stock (SCPH)